Use of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort

Scandinavian Journal of Urology

Volumn 49, Issue 2, 2015, Pages 127-132

  Patschan, Oliver ^a   Holmäng, Sten ^b   Hosseini, Abolfazl ^c   Liedberg, Fredrik ^a   Ljungberg, Börje ^d   Malmström, Per Uno ^e   Rosell, Johan ^f   Jahnson, Staffan ^f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Induction; Intravesical BCG; Stage T1; Survival; Urothelial bladder cancer

Indexed keywords

BCG VACCINE;

AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CYSTECTOMY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; AGE; HIGH VOLUME HOSPITAL; INTRAVESICAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; LOW VOLUME HOSPITAL; MORTALITY; MYCOBACTERIUM BOVIS; PATHOLOGY; REGISTER; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HOSPITALS, HIGH-VOLUME; HOSPITALS, LOW-VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; MYCOBACTERIUM BOVIS; NEOPLASM STAGING; REGISTRIES; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84924931711     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2014.968868     Document Type: Article

References (19)

1. Regionalt Cancercentrum (RCC). Nationellt kvalitetsregister for blåscancer, Rapport for diagnosår 2011. [In Swedish.]. Available from http://www.cancercentrum.se/Global/Diagnoser/blåscancer/rapporter/blasrapport2011.pdf
2. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
3. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
4. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-53.
5. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al. Current clinical practice gaps in the treatment of intermediate-and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742-50.
6. International Union Against Cancer. Sobin LH, Gospodarowicz MK, Wittekind C. The TNM classification of malignant tumours. 7th ed. Available from http://www.uicc.org/resources/tnm.
7. Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011;107: 404-8.
8. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105-8.
9. National Board of Health and Welfare, Stockholm, Sweden. Cause of Death Register. Available from http://www.socialstyrel-sen.se/register/dodsorsaksregistret.
10. Sabir EF, Holmäng S, Liedberg F, Ljungberg B, Malmstrom PU, Månsson W, et al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol 2013;47:483-90.
11. Gårdmark T, Bladstrom A, Hellsten S, Malmstrom PU. Members of the Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 2006;40:276-82.
12. Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, et al. Adjuvant intravesical bacillus Calmette-Guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:92-8.
13. Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol 2008;26:137-40.
14. Yuge K, Kikuchi E, Matsumoto K, Takeda T, Miyajima A, Oya M. Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? Jpn J Clin Oncol 2011;41:565-70.
15. Lamm DL, Van der Mejden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
16. Duchek M, Johansson R, Jahnson S, Mestad O, Hellstrom P, Hellsten S, et al. Members of the Urothelial Cancer Group of the Nordic Association of Urology. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25-31.
17. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-72.
18. Regionalt Cancercentrum (RCC): National Guidelines for Cancer in the Urinary Bladder, Ureter, Urethra and Renal Pelvis (Nationellt Vårdprogram for Cancer I urinblåsa, urinledare, urinror och njurbäcken) 2013. [In Swedish.]. Available from http://www.-cancercentrum.se/Global/RCC%20Samverkan/Dokument/Vår-dprogram/NatVP-cancer-urinvägarna-130523-final.pdf
19. Divrik RT, Sahin AF, Yildirim Ü, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010;58:185-90.